ArticleBiology direct2019
A novel framework for horizontal and vertical data integration in cancer studies with application to survival time prediction models.
Article in Biology direct, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The role of AI for improved management of breast cancer: Enhanced diagnosis and health disparity mitigation.Computer methods and programs in biomedicine · 2025Review
- Optimizing data linkage for maximizing the potential of Luxembourg's national cancer registry: a comprehensive scoping review.Frontiers in oncology · 2025Review
- Prediction of Composite Clinical Outcomes for Childhood Neuroblastoma Using Multi-Omics Data and Machine Learning.International journal of molecular sciences · 2024Article
- Scoping Review: Methods and Applications of Spatial Transcriptomics in Tumor Research.Cancers · 2024Article
- ASAS-NANP symposium: mathematical modeling in animal nutrition-Making sense of big data and machine learning: how open-source code can advance training of animal scientists.Journal of animal science · 2023Article
- Article
- Global mapping of cancers: The Cancer Genome Atlas and beyond.Molecular oncology · 2021Review
- Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer.Discover oncology · 2021Review
- Emerging roles of the HECT-type E3 ubiquitin ligases in hematological malignancies.Discover oncology · 2021Review
- The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome.Oncogene · 2021Article
- Recent advances in cancer immunotherapy.Discover oncology · 2021Review
- Understanding p53 tumour suppressor network.Biology direct · 2021Article
- Central vascular ligation and mesentery based abdominal surgery.Discover oncology · 2021Review
- Low level of plasminogen increases risk for mortality in COVID-19 patients.Cell death & disease · 2021Article
- NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network.Biology direct · 2021Article
- Feasibility and outcomes of ERAS protocol in elective cT4 colorectal cancer patients: results from a single-center retrospective cohort study.World journal of surgical oncology · 2021Article
- Assisted estimation of gene expression graphical models.Genetic epidemiology · 2021Article
- Vertical integration methods for gene expression data analysis.Briefings in bioinformatics · 2021Review
- Polymorphism on human aromatase affects protein dynamics and substrate binding: spectroscopic evidence.Biology direct · 2021Article
- New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP.Discover oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently high-throughput technologies have been massively used alongside clinical tests to study various types of cancer. Data generated in such large-scale studies are heterogeneous, of different types and formats. With lack of effective integration strategies novel models are necessary for efficient and operative data integration, where both clinical and molecular information can be effectively joined for storage, access and ease of use. Such models, combined with machine learning methods for accurate prediction of survival time in cancer studies, can yield novel insights into disease development and lead to precise personalized therapies.
resultsWe developed an approach for intelligent data integration of two cancer datasets (breast cancer and neuroblastoma) - provided in the CAMDA 2018 'Cancer Data Integration Challenge', and compared models for prediction of survival time. We developed a novel semantic network-based data integration framework that utilizes NoSQL databases, where we combined clinical and expression profile data, using both raw data records and external knowledge sources. Utilizing the integrated data we introduced Tumor Integrated Clinical Feature (TICF) - a new feature for accurate prediction of patient survival time. Finally, we applied and validated several machine learning models for survival time prediction.
conclusionWe developed a framework for semantic integration of clinical and omics data that can borrow information across multiple cancer studies. By linking data with external domain knowledge sources our approach facilitates enrichment of the studied data by discovery of internal relations. The proposed and validated machine learning models for survival time prediction yielded accurate results. REVIEWERS: This article was reviewed by Eran Elhaik, Wenzhong Xiao and Carlos Loucera.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.